Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.62 USD | +5.54% | +11.73% | +104.52% |
May. 14 | Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours | MT |
May. 14 | Transcript : Taysha Gene Therapies, Inc., Q1 2024 Earnings Call, May 14, 2024 |
Evolution of the average Target Price on Taysha Gene Therapies, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Taysha Gene Therapies, Inc.
Piper Sandler | |
Chardan Research | |
Needham & Co. | |
Cantor Fitzgerald | |
Truist Securities | |
Canaccord Genuity | |
Baird | |
Morgan Stanley | |
SMBC Nikko | |
BTIG | |
Jefferies & Co. | |
JMP Securities | |
Wells Fargo Securities | |
Goldman Sachs | |
Wedbush | |
Oppenheimer | |
Guggenheim | |
Chardan |
EPS Revisions
- Stock Market
- Equities
- TSHA Stock
- Consensus Taysha Gene Therapies, Inc.